Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Dr Andrew A. Parsons
Director of Reciprocal Minds Limited & Chairman of Pharmasum Therapeutics AS
About the author:
Dr Andrew A Parsons initially trained as a Pharmacologist and Neuroscientist and has over 90 peer reviewed publications, several patents and contributed to Educational Books in Science and Medicine. His former scientific focus was in areas of neuroplasticity and neurodegeneration. He played key roles on individual projects from initial idea through development and the market place. Working across traditional organisational and cultural boundaries he was instrumental in creating External Innovation platforms within a large Pharma company. Through this he became interested the impact of Human Factors on operational processes. He is a member of the Pharmaceutical Special Interest group and an associate member of the Chartered Institute of Ergonomics and Human Factors.
He is the Director of Reciprocal Minds Limited which supports individuals and groups undergoing personal and professional development and challenges to health and wellbeing. He is the co-author of “Leading with Presence, what it is, why it matters and how to get it?” He is also the Chairman of Pharmasum Therapeutics AS, an early stage Biotech company.
Posts by Dr Andrew A. Parsons
Posted on September 6th, 2017 in Pharma R&D
Opinions matter; they can drive our behaviors. Within the context of Pharma R&D, it is important to harness the benefits of different views, to think outside the box, innovate and beat the safety of group thinking.
Posted on August 14th, 2017 in Pharma R&D
To maximize value to payers, patients, and practitioners, pharma R&D wants to ensure that new medicines are given to the right patient, at the right time and at the right dose. To do this appropriately, we need ways to classify or diagnose patient groups.
Posted on August 7th, 2017 in Pharma R&D
A designer colleague once described to me the key issue involved in many of their creative design projects. It is finding the best balance between quality, speed, and cost. From a buyer perspective, we desire high quality, rapid delivery, and low cost. (more…)
Posted on July 24th, 2017 in Pharma R&D
With recent failures of large Phase 3 studies targeting the amyloid pathways, there is perhaps a need for some good news for scientists, clinicians, health services and the general public. Recently, there was some good news in the media. (more…)